These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 9149145

  • 1. Stabilization of a recombinant Fv fragment by base-loop interconnection and V(H)-V(L) permutation.
    Brinkmann U, Di Carlo A, Vasmatzis G, Kurochkina N, Beers R, Lee B, Pastan I.
    J Mol Biol; 1997 Apr 25; 268(1):107-17. PubMed ID: 9149145
    [Abstract] [Full Text] [Related]

  • 2. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
    Reiter Y, Pai LH, Brinkmann U, Wang QC, Pastan I.
    Cancer Res; 1994 May 15; 54(10):2714-8. PubMed ID: 8168102
    [Abstract] [Full Text] [Related]

  • 3. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin.
    Chaudhary VK, Queen C, Junghans RP, Waldmann TA, FitzGerald DJ, Pastan I.
    Nature; 1989 Jun 01; 339(6223):394-7. PubMed ID: 2498664
    [Abstract] [Full Text] [Related]

  • 4. Helix-stabilized Fv (hsFv) antibody fragments: substituting the constant domains of a Fab fragment for a heterodimeric coiled-coil domain.
    Arndt KM, Müller KM, Plückthun A.
    J Mol Biol; 2001 Sep 07; 312(1):221-8. PubMed ID: 11545598
    [Abstract] [Full Text] [Related]

  • 5. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
    Salvatore G, Beers R, Margulies I, Kreitman RJ, Pastan I.
    Clin Cancer Res; 2002 Apr 07; 8(4):995-1002. PubMed ID: 11948105
    [Abstract] [Full Text] [Related]

  • 6. Generation of a single-chain Fv fragment for the monitoring of deoxycholic acid residues anchored on endogenous proteins.
    Kobayashi N, Ohtoyo M, Wada E, Kato Y, Mano N, Goto J.
    Steroids; 2005 Apr 07; 70(4):285-94. PubMed ID: 15784283
    [Abstract] [Full Text] [Related]

  • 7. Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells.
    Scherf U, Benhar I, Webber KO, Pastan I, Brinkmann U.
    Clin Cancer Res; 1996 Sep 07; 2(9):1523-31. PubMed ID: 9816329
    [Abstract] [Full Text] [Related]

  • 8. Improved stability and yield of Fv targeted superantigen by introducing both linker and disulfide bond into the targeting moiety.
    Hao HJ, Jiang YQ, Zheng YL, Ma R, Yu DW.
    Biochimie; 2005 Aug 07; 87(8):661-7. PubMed ID: 15927340
    [Abstract] [Full Text] [Related]

  • 9. Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins.
    Reiter Y, Pastan I.
    Clin Cancer Res; 1996 Feb 07; 2(2):245-52. PubMed ID: 9816166
    [Abstract] [Full Text] [Related]

  • 10. Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size, and stability.
    Bera TK, Pastan I.
    Bioconjug Chem; 1998 Feb 07; 9(6):736-43. PubMed ID: 9815167
    [Abstract] [Full Text] [Related]

  • 11. Production of functionalized single-chain Fv antibody fragments binding to the ED-B domain of the B-isoform of fibronectin in Pichia pastoris.
    Marty C, Scheidegger P, Ballmer-Hofer K, Klemenz R, Schwendener RA.
    Protein Expr Purif; 2001 Feb 07; 21(1):156-64. PubMed ID: 11162401
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Anti-estradiol-17beta single-chain Fv fragments: Generation, characterization, gene randomization, and optimized phage display.
    Kobayashi N, Kato Y, Oyama H, Taga S, Niwa T, Sun P, Ohtoyo M, Goto J.
    Steroids; 2008 Dec 22; 73(14):1485-99. PubMed ID: 18824188
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site.
    Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, Crawford RS, Weiner LM, Marks C, Marks JD.
    J Mol Biol; 1996 Nov 08; 263(4):551-67. PubMed ID: 8918938
    [Abstract] [Full Text] [Related]

  • 19. Crystal structure of the disulfide-stabilized Fv fragment of anticancer antibody B1: conformational influence of an engineered disulfide bond.
    Almog O, Benhar I, Vasmatzis G, Tordova M, Lee B, Pastan I, Gilliland GL.
    Proteins; 1998 May 01; 31(2):128-38. PubMed ID: 9593187
    [Abstract] [Full Text] [Related]

  • 20. Rapid and specific uptake of anti-Tac disulfide-stabilized Fv by interleukin-2 receptor-bearing tumors.
    Webber KO, Kreitman RJ, Pastan I.
    Cancer Res; 1995 Jan 15; 55(2):318-23. PubMed ID: 7812965
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.